{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CorMedix, Inc.
Is CorMedix, Inc. overvalued or undervalued?
As of October 17, 2025, CorMedix, Inc. has shifted from an attractive to a very attractive valuation grade, indicating it is undervalued with a PEG ratio of 0.42 and a high ROCE of 38.54%, despite a high P/E ratio of 55, and has outperformed the S&P 500 with a three-year return of 229.45%.
CorMedix, Inc. Experiences Valuation Adjustment Reflecting Shift in Financial Standing
CorMedix, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 55 and a price-to-book value of 8.25. The company demonstrates strong operational efficiency with a PEG ratio of 0.42 and a ROCE of 38.54%, positioning it favorably against peers like Xeris Biopharma Holdings.
Is CorMedix, Inc. overvalued or undervalued?
As of October 17, 2025, CorMedix, Inc. is considered very attractive and undervalued due to a PEG ratio of 0.42, a high P/E ratio of 55 supported by a strong ROCE of 38.54%, and a year-to-date return of 25.68%, outperforming the S&P 500.
Is CorMedix, Inc. overvalued or undervalued?
As of October 17, 2025, CorMedix, Inc. is considered very attractive due to its strong growth potential indicated by a PEG ratio of 0.42, a favorable valuation profile with a P/E of 55, and solid performance metrics, including a year-to-date return of 25.68% and a ROCE of 38.54%.
Is CorMedix, Inc. technically bullish or bearish?
As of September 10, 2025, CorMedix, Inc. shows a mildly bullish trend with daily moving averages supporting this stance, despite mixed signals from weekly indicators and strong long-term performance compared to the S&P 500.
Is CorMedix, Inc. overvalued or undervalued?
As of August 7, 2025, CorMedix, Inc. is considered very attractive due to its undervalued status, strong growth potential indicated by a PEG ratio of 0.42, favorable operational efficiency with ROCE of 38.54% and ROE of 14.95%, and a year-to-date return of 44.32% that significantly outpaces the S&P 500's 12.22%.
CorMedix Stock Hits Day Low of $11.50 Amid Price Pressure
CorMedix, Inc. faced a significant stock price decline today, reaching an intraday low. However, the company has demonstrated strong financial performance over the past year, with substantial growth in net profit and pre-tax profit, alongside solid operating cash flow and a favorable return on equity.
Is CorMedix, Inc. overvalued or undervalued?
As of May 6, 2025, CorMedix, Inc. is considered overvalued with a high P/E ratio of 55 and an EV to EBITDA ratio of 57.92, despite a strong year-to-date return of 104.44%, which exceeds the S&P 500's 2.44%.
Is CorMedix, Inc. technically bullish or bearish?
As of May 6, 2025, the market trend is bullish, supported by strong indicators like bullish MACD, Bollinger Bands, and moving averages across multiple time frames, along with a significant price increase.
Who are in the management team of CorMedix, Inc.?
As of March 2022, the management team of CorMedix, Inc. includes Myron Kaplan (Independent Chairman), Khoso Baluch (CEO), Paulo Costa, Gregory Duncan, Janet Dillione, Alan Dunton, and Steven Lefkowitz (all Directors). They oversee the company's strategic direction and operations.
What does CorMedix, Inc. do?
CorMedix, Inc. is a micro-cap pharmaceutical and medical device company focused on developing products for infectious and inflammatory diseases, with recent net sales of $39 million and a net profit of $21 million. The company has a market cap of $945.48 million and key financial metrics include a P/E ratio of 55.00 and a return on equity of 14.95%.
How big is CorMedix, Inc.?
As of Jun 18, CorMedix, Inc. has a market capitalization of 945.48 million and reported net sales of 82.56 million and net profit of 17.17 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
